2022-RA-941-ESGO CEBOC, a single-arm phase II trial to evaluate the safety of cediranib in the prevention of bowel perforation in platinum resistant ovarian cancer

Alexander Murphy, Catharine Porter, Ann White, Alys Irving, Ruby Ray, Angela Casbard, Tracie-Ann Madden, Reem Mahmood, Robert Morgan, Julia Pugh, Chelsey Wheeler, Victoria Roberts (+6 others)
2022 Ovarian cancer   unpublished
Randomisation is stratified by surgery planned time point (neoadjuvant vs. adjuvant), surgical outcome (R0 vs R1), response to chemotherapy followed by bev (CR/NED vs. PR/ SD) and study center. Primary endpoint is PFS per RECIST v1.1. Secondary endpoints are PFS2, quality of life, daily activity, time to next medical intervention, time to next subsequent therapy, safety assessments and OS. So far 35 patients are randomised in the study.
doi:10.1136/ijgc-2022-esgo.599 fatcat:oerajvswhzcd3mcw6w5snxwjly